NASDAQ : LAB
Standard BioTools Inc. — Key statistics
Healthcare · Medical Devices · United States
Last price 0.61 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 239.47M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 239.47M |
| Enterprise Value | -209.16M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 392.58M |
| Shares Outstanding | 392.58M |
| Shares Change (YoY) | +2.76% |
| Shares Change (QoQ) | +0.69% |
| Owned by Insiders (%) | 1.82% |
| Owned by Institutions (%) | 24.40% |
| Float | 185.68M |
Ratios
| Measure | Value |
|---|
| PE Ratio | 2.78 |
| Forward PE | n/a |
| PS Ratio | 2.83 |
| Forward PS | 2.91 |
| PB Ratio | 0.44 |
| P/TBV Ratio | 0.44 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 9.10 |
| Quick Ratio | 8.67 |
| Debt / Equity | 0.05 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -2,409.08 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -11.18% |
| Return on Assets (ROA) | -6.61% |
| Return on Invested Capital (ROIC) | -7.67% |
| Return on Capital Employed (ROCE) | -10.98% |
| Weighted Average Cost of Capital (WACC) | 10.47% |
| Revenue Per Employee | $217,473 |
| Profits Per Employee | $218,267 |
| Employee Count | 389 |
| Asset Turnover | 0.14 |
| Inventory Turnover | 2.03 |
Taxes
| Measure | Value |
|---|
| Income Tax | -37.05M |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.35 |
| 52-Week Price Change | -48.74% |
| 50-Day Moving Average | 0.68 |
| 200-Day Moving Average | 0.92 |
| Relative Strength Index (RSI) | 38.21 |
| Average Volume (20 Days) | 850,543 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 2.45M |
| Short Previous Month | 2.52M |
| Short % of Shares Out | 0.62% |
| Short % of Float | 1.32% |
| Short Ratio (days to cover) | 2.55 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 84.60M |
| Gross Profit | 42.71M |
| Operating Income | -62.64M |
| Pretax Income | -90.98M |
| Net Income | 84.91M |
| EBITDA | -53.07M |
| EBIT | -62.64M |
| Earnings Per Share (EPS) | $0.22 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 476.72M |
| Total Debt | 28.09M |
| Net Cash | 448.63M |
| Net Cash Per Share | $1.14 |
| Equity (Book Value) | 539.97M |
| Book Value Per Share | 1.38 |
| Working Capital | 460.07M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -80.30M |
| Capital Expenditures | -2.28M |
| Depreciation & Amortization | 9.56M |
| Net Borrowing | n/a |
| Free Cash Flow | -82.58M |
| FCF Per Share | -$0.21 |
Margins
| Measure | Value |
|---|
| Gross Margin | 50.49% |
| Operating Margin | -74.04% |
| Pretax Margin | -107.55% |
| Profit Margin | 100.37% |
| EBITDA Margin | -62.74% |
| EBIT Margin | -74.04% |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -2.76% |
| Shareholder Yield | -2.76% |
| Earnings Yield | 35.99% |
| FCF Yield | -34.48% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | 0.14% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 1.28 |
| Piotroski F-Score | 3 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside | |